ImmunoMet
Developer of novel anti-tumor and immuno-oncology therapies designed to treat cancer patients. The company's therapies include drugs and metabolic regulators to increase patient survival by disrupting...
Valuation
$46M
Latest known
Share Price
N/A
Total Raised
$42.9M
Last Round
N/A